Crossmark Global Holdings Inc. Acquires 3,625 Shares of Johnson & Johnson (NYSE:JNJ)

Crossmark Global Holdings Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% in the 1st quarter, HoldingsChannel reports. The firm owned 42,312 shares of the company’s stock after acquiring an additional 3,625 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Johnson & Johnson were worth $7,017,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Lantz Financial LLC lifted its position in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after acquiring an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth $453,000. State of Wyoming boosted its holdings in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Joel Isaacson & Co. LLC boosted its holdings in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after purchasing an additional 2,526 shares during the last quarter. Finally, Range Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after acquiring an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

Shares of Johnson & Johnson stock opened at $155.76 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The business has a 50-day moving average price of $153.67 and a 200 day moving average price of $154.25. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market cap of $374.77 billion, a P/E ratio of 17.33, a P/E/G ratio of 2.35 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.